ZVRA peer analysis
Zevra Therapeutics (ZVRA) against its competitors: price, today's move, 1-year return and market value side by side.
ZVRA and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ALKS Alkermes | $46.01 | 3.30% | 43.35% | $7.71B |
| ANRO Alto Neuroscience | $25.03 | 14.45% | 93.71% | – |
| GHRS GH Research | $18.61 | 0.92% | 35.69% | – |
| JAZZ Jazz Pharmaceuticals | $237.00 | 4.26% | 65.66% | $15.06B |
| MPLT MapLight Therapeutics | $7.60 | 22.19% | -61.13% | – |
| NBIX Neurocrine Biosciences | $164.63 | 3.05% | 3.91% | $16.81B |
| NMRA Neumora Therapeutics | $0.49 | -13.96% | -81.41% | – |
| PRAX Praxis Precision Medicines | $279.00 | 6.25% | 59.49% | – |
| SUPN Supernus Pharmaceuticals | $26.16 | -2.17% | -53.09% | $1.64B |
| XENE Xenon Pharmaceuticals | $39.39 | 4.54% | -2.53% | $3.80B |
| ZVRA Zevra Therapeutics | $11.45 | 8.74% | 4.57% | – |
- ZVRA's peers: ALKS (Alkermes), ANRO (Alto Neuroscience), GHRS (GH Research), JAZZ (Jazz Pharmaceuticals), MPLT (MapLight Therapeutics), NBIX (Neurocrine Biosciences), NMRA (Neumora Therapeutics), PRAX (Praxis Precision Medicines).
Updated 2026-11-07 11:56 UTC